Selecting Safe Chemotherapy Regimens in Older Breast Cancer Patients

Video

This video reviews the evidence for safe and effective chemotherapy regimens in older patients with breast cancer and highlights the need for geriatric assessment in this population.

In breast cancer trials, most chemotherapy regimens are studied in younger, healthier patients. In practice, many of these regimens have been shown to be too toxic for older women, with higher rates of hospitalization among these patients.

In this video, Hans Wildiers, MD, PhD, of University Hospitals Leuven in Belgium, reviews some of the regimens that are too toxic, highlights one regimen shown to be feasible, and discusses the need for geriatric assessment in this population.  

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.